![]() ![]() ![]() The Nuvaxovid (Novavax) vaccine is provisionally approved for adults. ![]() Third, the large sample size means that we can identify rare events that might not be picked up through clinical trials. Up-to-date information for Spikevax (Moderna), including details of potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals). Second, this was a population-based study of prospectively recorded data and avoided recall and selection biases linked to case reports. First, the UK offered an ideal place to carry out this study given three vaccinations have been rolled out at speed and scale. That's in contrast to less than one in 100 after their first or second shot. We’ve now extended these observations by including 38 million adults in England receiving both adenovirus and mRNA vaccine types. Clinical trials show up to one in 20 (Pfizer) and one in 10 people (Moderna) will get swollen or sore lymph nodes following a booster. Professor Nicholas Mills, British Heart Foundation Chair of Cardiology at the University of Edinburgh, and co-lead author said: “Our findings are consistent with those from a similar study of people receiving the Pfizer-BioNTech vaccine from Israel and two studies of people receiving the Moderna vaccine in the US. This will be important to the public, clinicians and policy makers as although myocarditis and pericarditis were not observed as risks in COVID-19 vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population.” "This is also the first study to investigate the association between cardiac events and the Oxford AstraZeneca vaccine. Martina Patone, Medical Statistician at the Nuffield Department of Primary Care Health Sciences, University of Oxford, and co-lead author said: “This is the largest study to date of acute cardiac outcomes after COVID-19 vaccination or infection and the first to compare risk of cardiac events between different vaccine products and COVID-19 infection. "However, it is important that we know about and identify the risks of these rare conditions from vaccines as well, to ensure that clinicians know what to look for, aid earlier diagnosis, and inform clinical decision making and resource management.” "For example, we estimated between one and 10 extra events of myocarditis in one million people vaccinated with a first or second dose, but 40 extra cases in one million people infected with COVID-19. And what we’ve found here continues this finding – whilst there are some increased risks of rare heart related complications associated with vaccines these are much lower than the risk associated with getting COVID-19. Julia Hippisley-Cox, Professor of Clinical Epidemiology and General Practice at the University of Oxford, and study lead said: “We know the COVID-19 vaccines are highly effective at reducing risks of severe outcomes from COVID-19 infection. While a link between heart inflammation, such as pericarditis and myocarditis, and vaccination was not observed during clinical trials of the most common COVID-19 vaccines, shortly after vaccines began rolling out across the globe concerns began to be raised about a link – in particular, to myocarditis and especially in younger people. ![]()
0 Comments
Leave a Reply. |